

Clinical Global Impression – Severity

Both subjects with a pre-synaptic mutation type were randomized to the amifampridine/placebo treatment arm. At Day 0 (Baseline) one subject reported a severity of illness of 3 (mildly ill) and at Day 8 both subjects reported a severity of illness of 4 (moderately ill). At Day 21 (Baseline) both subjects reported a severity of illness of 4 (moderately ill) and at Day 29 one subject reported a severity of illness of 3 (mildly ill) while the other subject reported a severity of illness of 4 (moderately ill). For subjects with a post-synaptic mutation randomized to the amifampridine/placebo treatment arm, at Day 0 (Baseline) three subjects reported a severity of illness of 3 (mildly ill) while at Day 8 three subjects reported a severity of illness of 3 (mildly ill) and three subjects reported a severity of illness of 2 (borderline mentally ill). At Day 21 (Baseline) three subjects reported a severity of illness of 1 (normal, not at all ill), one subject reported a severity of illness of 2 (borderline mentally ill), and two subjects reported a severity of illness of 3 (mildly ill) while at Day 29 two subjects reported a severity of illness of 1 (normal, not ill at all), two subjects reported a severity of illness of 2 (borderline mentally ill), and two subjects reported a severity of illness of 3 (mildly ill). For subjects with a post-synaptic mutation randomized to the placebo/amifampridine treatment arm, at Day 0 (Baseline) one subject reported a severity of illness of 2 (borderline mentally ill), three subjects reported a severity of illness of 3 (mildly ill), and two subjects reported a severity of illness of 4 (moderately ill) while at Day 8 one subject reported a severity of illness of 1 (normal, not at all ill), three subjects reported a severity of illness of 2 (borderline mentally ill), one subject reported a severity of illness of 3 (mildly ill), and one subject reported a severity of illness of 4 (moderately ill). At Day 21 (Baseline) one subject reported a severity of illness of 1 (normal, not ill at all), one subject reported a severity of illness of 2 (borderline mentally ill), three subjects reported a severity of illness of 3 (mildly ill), and two subjects reported a severity of illness of 4 (moderately ill) while at Day 29 one subject reported a severity of illness of 1 (normal, not at all ill), one subject reported a severity of illness of 2 (borderline mentally ill), four subjects reported a severity of illness of 3 (mildly ill), and one subject reported a severity of illness of 4 (moderately ill). There were no statistically significant differences for CGI-S in subjects treated with amifampridine phosphate or placebo overall or by mutation type.